49 results
F-1
EX-10.13
AMYT
Amryt Pharma Plc
23 Jun 20
Registration statement (foreign)
5:21pm
"
means the price at which a Share must be subscribed on exercise of an Option;
"Participant"
means any Nominated Person (or, in the event of his death … certificate.
DEATH AND TRANSFER OF RIGHTS
In the event of the death of a Participant before the Final Option Date the personal representative
DRS/A
EX-10.13
AMYT
Amryt Pharma Plc
11 May 20
Draft registration statement (amended)
12:00am
"
means the price at which a Share must be subscribed on exercise of an Option;
"Participant"
means any Nominated Person (or, in the event of his death … certificate.
DEATH AND TRANSFER OF RIGHTS
In the event of the death of a Participant before the Final Option Date the personal representative
F-1/A
EX-10.13
AMYT
Amryt Pharma Plc
6 Jul 20
Registration statement (foreign) (amended)
5:28pm
Nominated Person (or, in the event of his death, his personal representative) who is for the time being the holder of an Equity Incentive … basis, at the Participant’s election; and/or
a Participant is entitled to receive Dividend Equivalents.
In the event of the death, retirement, early
F-1/A
EX-10.14
AMYT
Amryt Pharma Plc
6 Jul 20
Registration statement (foreign) (amended)
5:28pm
in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death … be an Employee (except in the event of the U.S. Participant’s death or Disability, in which case longer periods apply). The U.S. Option will no longer
F-1
EX-3.1
AMYT
Amryt Pharma Plc
23 Jun 20
Registration statement (foreign)
5:21pm
Transfer by renunciation
TRANSMISSION OF SHARES
On death
Election of person entitled by transmission
Transfer notice
Rights on transmission
INCREASE …
Notices to be in writing
Service of notice on members
Notice in case of death, bankruptcy or mental disorder
Evidence of service
Notice binding
6-K
EX-99.1
8f7eb g6vmxg3aq
28 Feb 22
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA
12:00pm
6-K
EX-99.1
wo1zk5
23 Jun 22
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB
7:26am
6-K
EX-99.1
c0p 1lsdfpw1
3 Nov 20
Current report (foreign)
8:45am
6-K
EX-99.6
8v8st8yiwky2g5g3ad5
31 Jan 22
Current report (foreign)
7:32am
424B3
f73qchcj1f5v81 ry
28 Feb 22
Prospectus supplement
12:02pm
424B3
9v0vf
28 Feb 22
Prospectus supplement
12:01pm
6-K
EX-99.1
8tj6xmkqc
23 Nov 21
Amryt Provides Update on Regulatory Review Process for Oleogel-S1
8:04am
6-K
EX-99.1
asvplj
24 Jun 22
Filsuvez® recently approved by the European Commission for the treatment of EB
7:18am
424B3
5nvuc6 00sq9l5
23 Nov 21
Prospectus supplement
8:06am
6-K
EX-99.2
u86o14t1qh nq
4 Aug 22
Results of Annual General Meeting
7:38am
6-K
EX-99.5
9luk9qxcaejwme5pa8
3 Nov 22
Current report (foreign)
7:44am
6-K
EX-99.4
cysgr0wbzfunvn 243du
11 May 22
Current report (foreign)
4:30pm
6-K
EX-99.3
8fgu4po3chfwbf
31 Mar 22
Results of General Meeting
8:41am